Hailing Pharmaceutical – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:55 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Hailing Pharmaceutical – CRI Report https://www.cri-report.com 32 32 Research Report on China’s Mecobalamin Market, 2021-2025 https://www.cri-report.com/research-report-on-chinas-mecobalamin-market-2021-2025/ Mon, 19 Jul 2021 02:43:40 +0000 https://www.cri-report.com/?post_type=product&p=13244 Due to the impact of the new covid-19 pandemic on the overall treatment services of hospitals, the sales of Mecobalamin in the Chinese Market declined to CNY529 million in 2020, with a CAGR of -3.44% from 2016 to 2020.

The post Research Report on China’s Mecobalamin Market, 2021-2025 first appeared on CRI Report.

]]> Mecobalamin is an endogenous coenzyme B12, which has a good effect on neuronal conduction compared with other types of vitamin B12, and can promote nucleic acid-protein-lipid metabolism through methyl conversion reaction. It is mainly used in clinical practice for peripheral neuropathy and megaloblastic anemia caused by vitamin B12 deficiency. In addition, Mecobalamin has been widely used in clinical practice to promote nerve anastomosis in reinserted fingers, promote sensory recovery, and improve neurological symptoms caused by disc herniation, sciatica, facial palsy, herpes zoster, etc.

Eisai’s Mecobalamin, whose trade name is Methycocal, was approved to enter the Chinese market in 1998, followed by other companies’ generic drugs. According to CRI’s market research, by 2020, there will be several suppliers in the mecobalamin market in China, with North China Pharmaceutical Company Limited as the main supplier.

According to CRI’s research data, the sales of Mecobalamin in the Chinese Market are relatively stable from 2016 to 2019. Due to the impact of the new crown epidemic on the overall treatment services of hospitals, the sales of Mecobalamin in the Chinese Market declined to CNY529 million in 2020, with a CAGR of -3.44% from 2016 to 2020.

CRI expects the sales volume of Mecobalamin in the Chinese Market to recover in 2021-2025 with the effective mitigation of the New Crown epidemic. Meanwhile, Eisai’s Mecobalamin has been selected by the Chinese government for the third batch of volume procurement, and the sales volume is expected to rise significantly. With the improvement and popularization of medical services in China, the demand for Mecobalamin will continue to increase, and the sales volume of Mecobalamin in China will have some upside.

 

Key Points：

  • -Impact of COVID-19 on China’s Mecobalamin Market
  • -Development Environment of Mecobalamin in China
  • -Sales Volume of Mecobalamin in China
  • -Sales Volume and Sales Value of Mecobalamin in Different Regions of China
  • -Major Mecobalamin Manufacturers in China and Their Market Shares
  • -Market Prices of Mecobalamin in China
  • -Major Mecobalamin Manufacturers in China
  • -Prospect on China’s Mecobalamin Market, 2021-2025

The post Research Report on China’s Mecobalamin Market, 2021-2025 first appeared on CRI Report.

]]>